Market cap
₹249 Cr
Recently Viewed
Clear AllNSE: LOTUSEYE | BSE: 532998
₹120.17
₹-3.38
(-2.74%)
As on 28-Apr-2026IST
Market cap
₹249 Cr
Revenue (TTM)
₹52 Cr
P/E Ratio
381.8
P/B Ratio
4.1
Div. Yield
0 %
Today’s Range
52 Week Range
Liquidity
Net Profit (TTM)
₹1 Cr
ROE
1.2 %
ROCE
3.1 %
Industry P/E
395.23
EV/EBITDA
62.4
Debt to Equity
0
Book Value
₹29
EPS
₹0.3
Face value
10
Shares outstanding
20,796,330
CFO
₹41.22 Cr
EBITDA
₹45.52 Cr
Net Profit
₹16.35 Cr
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Lotus Eye Hosp
| 0.8 | 17.0 | -6.3 | 62.0 | 24.3 | 22.7 | 20.7 |
|
BSE Healthcare
| 2.6 | 5.0 | 8.0 | 6.4 | 25.0 | 13.8 | 11.1 |
|
Company
|
2025
|
2024
|
2023
|
2022
|
2021
|
2020
|
2019
|
|---|---|---|---|---|---|---|---|
|
Lotus Eye Hosp
| 72.4 | -20.9 | 8.9 | 47.5 | 50.9 | 43.5 | -21.2 |
|
BSE Small Cap
| -6.6 | 29.0 | 47.5 | -1.8 | 62.8 | 32.1 | -6.8 |
|
BSE Healthcare
| -3.3 | 43.1 | 37.0 | -12.1 | 20.9 | 61.4 | -3.5 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price (₹) | Market Cap (₹ Cr) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
Lotus Eye Hosp
|
120.2 | 249.4 | 51.6 | 0.7 | 1.3 | 1.1 | 381.8 | 4.1 |
| 63.5 | 65.4 | 24.2 | 1.5 | 5.5 | 11 | 44.6 | 5.1 | |
| 705.3 | 36,540.5 | 4,461.2 | 397.5 | 13.4 | 9.1 | 111.7 | 7.9 | |
| 441.6 | 14,003.2 | 1,976.2 | 160.7 | 14.1 | 6.7 | 111.1 | 7.1 | |
| 1,411.7 | 23,668.0 | 2,662.8 | 533.1 | 22.9 | 24.1 | 44.8 | 9.2 | |
| 662.3 | 26,529.2 | 3,626.9 | 315.0 | 15.0 | 13.3 | 88.2 | 11.4 | |
| 127.0 | 42.6 | 16.5 | -1.4 | 6.6 | -3.6 | -- | 1.1 | |
| 1,241.9 | 12,598.4 | 1,613.3 | 259.9 | 23.0 | 17.3 | 48.9 | 7.9 | |
| 17.2 | 39.1 | 0.0 | -8.7 | -- | -64.3 | -- | 3.4 | |
| 70.2 | 30.0 | 27.2 | -2.0 | -3.4 | -287.5 | -- | -28.7 |
3 min read•By Research Desk
Lotus Eye Hospital and Institute Limited, a specialty eye care hospital, provides eye care and related services in India. The company offers ReLEx SMILE, a refractive lenticule extraction small incision lenticule extraction; touch free laser; lasik... eye surgery; Epi-LASIK, an epithelial laser in situ keratomileusis; Intralase, a blade-free technique to create the corneal flap; Zyoptix Supracor laser technology; robotic femto laser cataract surgery; phacoemulsification; paediatric eye care and squint surgery; and micro incision cataract surgery treatments. It provides treatment services for various eye problems, such as refractive, cataract, glaucoma, retinal disease/diabetic eye care, neuro ophthalmology, binocular vision, and cornea infections, as well as various eye related courses. The company was formerly known as Lotus Eye Care Hospital Limited and changed its name to Lotus Eye Hospital and Institute Limited in April 2013. Lotus Eye Hospital and Institute Limited was founded in 1989 and is based in Coimbatore, India. Read more
Incorporated
1997
Chairman
Kavetha Sundaramoorthy
Managing Director
Sangeetha Sundaramoorthy
Headquarters
Coimbatore, Tamil Nadu
Website
Looking for more details about Lotus Eye Hospital And Institute Ltd.’s IPO? Explore our IPO Details page.
Our rating system has guided millions of investors in the past 20 years.
Annual Reports
The share price of Lotus Eye Hospital And Institute Ltd is ₹120.17 (NSE) and ₹119.90 (BSE) as of 28-Apr-2026 IST. Lotus Eye Hospital And Institute Ltd has given a return of 24.28% in the last 3 years.
The P/E ratio of Lotus Eye Hospital And Institute Ltd is 381.85 times as on 28-Apr-2026, a 3 discount to its peers’ median range of 395.23 times.
The P/B ratio of Lotus Eye Hospital And Institute Ltd is 4.13 times as on 28-Apr-2026, a 4 discount to its peers’ median range of 4.28 times.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
|
2025
|
196.62
|
2.42
|
|
2024
|
40.31
|
1.98
|
|
2023
|
29.62
|
2.10
|
|
2022
|
37.18
|
2.03
|
|
2021
|
55.57
|
1.65
|
The 52-week high and low of Lotus Eye Hospital And Institute Ltd are Rs 147.00 and Rs 67.72 as of 28-Apr-2026.
Lotus Eye Hospital And Institute Ltd has a market capitalisation of ₹ 249 Cr as on 28-Apr-2026. As per SEBI classification, it is a Small Cap company.
Before investing in Lotus Eye Hospital And Institute Ltd, assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.